1.
Haroutunian, L, Neil, CA. Pulmonary complications of congenital heart disease: hemoptysis. Am Heart J
1972; 84: 540–559.
2.
Diller, GP, Gatzoulis, MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation
2007; 115: 1039–1050.
3.
Daliento, L, Somerville, J, Presbitero, P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J
1998; 19: 1845–1855.
4.
Coss-Bu, JA, Sachdeva, RC, Bricker, JT, et al. Hemoptysis: a 10-year retrospective study. Pediatrics
1997; 100: e7.
5.
Novikova, N, Hofmeyr, GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev
2010; 7: CD007872.
6.
Graff, GR. Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. Respiration
2001; 68: 91–94.
7.
Henry, DA, Carless, PA, Moxey, AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev
2007: CD001886.
8.
CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet
2010; 376: 23–32.
9.
Brinson, GM, Noone, PG, Mauro, MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med
1998; 157: 1951–1958.
10.
Hartnell, GG. Embolization in the treatment of acquired and congenital abnormalities of the heart and thorax. RadioGraphics
1993; 13: 1349–1362.